UY37803A - Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia - Google Patents

Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia

Info

Publication number
UY37803A
UY37803A UY0001037803A UY37803A UY37803A UY 37803 A UY37803 A UY 37803A UY 0001037803 A UY0001037803 A UY 0001037803A UY 37803 A UY37803 A UY 37803A UY 37803 A UY37803 A UY 37803A
Authority
UY
Uruguay
Prior art keywords
compositions
hemophilia
subject
methods
treat
Prior art date
Application number
UY0001037803A
Other languages
English (en)
Inventor
Akin Akinc
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of UY37803A publication Critical patent/UY37803A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un ARNi, por ejemplo, un ácido ribonucleico de hebra doble (ARNhd), composiciones dirigidas al gen Serpinc1 y métodos para usar dicho ARNi, por ejemplo, ARNhd, composiciones para tratar un evento de sangrado en un sujeto que tiene una hemofilia (por ejemplo, con o sin inhibidores).
UY0001037803A 2017-07-10 2018-07-10 Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia UY37803A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762530518P 2017-07-10 2017-07-10
US201762599223P 2017-12-15 2017-12-15
US201862614111P 2018-01-05 2018-01-05
US201862673424P 2018-05-18 2018-05-18

Publications (1)

Publication Number Publication Date
UY37803A true UY37803A (es) 2019-02-28

Family

ID=63036452

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037803A UY37803A (es) 2017-07-10 2018-07-10 Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia

Country Status (14)

Country Link
US (2) US20200163987A1 (es)
EP (1) EP3651852A1 (es)
JP (2) JP2020530442A (es)
KR (1) KR20200026960A (es)
CN (1) CN111093771A (es)
AU (2) AU2018301801A1 (es)
BR (1) BR112020000400A2 (es)
CA (1) CA3069150A1 (es)
CO (1) CO2020001354A2 (es)
IL (1) IL271646A (es)
SG (1) SG11201912243PA (es)
TW (1) TWI843703B (es)
UY (1) UY37803A (es)
WO (1) WO2019014187A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3188137A1 (en) 2020-06-22 2021-12-30 Genzyme Corporation Methods and compositions for treating hemophilia
WO2022076835A1 (en) * 2020-10-09 2022-04-14 Dyax Corp. Methods and apparatuses for modeling adamts13 and von willebrand factor interactions
WO2022120291A1 (en) 2020-12-06 2022-06-09 Genzyme Corporation Treatment of hemophilia with fitusiran
IL303452A (en) 2020-12-06 2023-08-01 Genzyme Corp Treatment of hemophilia with Fitusiran
TW202342065A (zh) 2021-12-22 2023-11-01 美商健臻公司 治療血友病的方法和組成物
WO2023240193A2 (en) 2022-06-08 2023-12-14 Genzyme Corporation Treatment of hemophilia with fitusiran in pediatric patients
WO2023240199A2 (en) 2022-06-08 2023-12-14 Genzyme Corporation Treatment of hemophilia with fitusiran
WO2024094701A1 (en) 2022-10-31 2024-05-10 Sanofi Assembly for a drug delivery device
WO2024094700A1 (en) 2022-10-31 2024-05-10 Sanofi Method for assembling an assembly for a drug delivery device and drug delivery device.
WO2024094706A1 (en) 2022-10-31 2024-05-10 Sanofi Audible indicator, indicator holder and method of assembling an audible indicator
WO2024094707A1 (en) 2022-10-31 2024-05-10 Sanofi Drug delivery device with feedback element and method for providing a user of a drug delivery device feedback regarding a dose dispensing process
WO2024094703A1 (en) 2022-10-31 2024-05-10 Sanofi Plunger for expelling a drug, drug delivery device, rear sub-assembly and corresponding methods
WO2024094702A1 (en) 2022-10-31 2024-05-10 Sanofi Device body for a drug delivery device, assembly for a drug delivery device and drug delivery device
WO2024094699A1 (en) 2022-10-31 2024-05-10 Sanofi Container holder and drug delivery device comprising the container holder
WO2024094698A1 (en) 2022-10-31 2024-05-10 Sanofi Front sub-assembly for a drug delivery device
WO2024094704A1 (en) 2022-10-31 2024-05-10 Sanofi Arrangement for a drug delivery device, drug delivery device and method for assembly
WO2024094705A1 (en) 2022-10-31 2024-05-10 Sanofi Drug delivery device having a two-part user indicator
WO2024097190A1 (en) 2022-11-02 2024-05-10 Genzyme Corporation Systems and methods for modeling thrombin-antithrombin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009284393B2 (en) * 2008-08-22 2014-09-25 Takeda Pharmaceutical Company Limited Methods for treating bleeding disorders
CN105848668A (zh) * 2013-11-04 2016-08-10 加利福尼亚大学董事会 治疗或预防与出血或低凝血相关联的病状的疗法
TW201607559A (zh) * 2014-05-12 2016-03-01 阿尼拉製藥公司 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
WO2016085852A1 (en) * 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
RU2754188C2 (ru) * 2015-12-07 2021-08-30 Джензим Корпорейшн Способы и композиции для лечения ассоциированного с serpinc1 расстройства

Also Published As

Publication number Publication date
TW201920670A (zh) 2019-06-01
EP3651852A1 (en) 2020-05-20
US20200163987A1 (en) 2020-05-28
SG11201912243PA (en) 2020-01-30
JP2023123756A (ja) 2023-09-05
RU2020105876A (ru) 2021-08-10
CN111093771A (zh) 2020-05-01
US20230158058A1 (en) 2023-05-25
AU2018301801A1 (en) 2020-02-06
IL271646A (en) 2020-02-27
BR112020000400A2 (pt) 2020-07-14
KR20200026960A (ko) 2020-03-11
AU2024204136A1 (en) 2024-07-11
CA3069150A1 (en) 2019-01-17
RU2020105876A3 (es) 2021-11-16
CO2020001354A2 (es) 2020-05-29
TWI843703B (zh) 2024-06-01
WO2019014187A1 (en) 2019-01-17
JP2020530442A (ja) 2020-10-22

Similar Documents

Publication Publication Date Title
UY37803A (es) Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia
CO2018006590A2 (es) Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1
CR20150493A (es) Composiciones de amri contra el componente c5 del complemento y métodos para su uso
CL2021002998A1 (es) Composiciones de arni contra tmprss6 y métodos para su uso (divisional de solicitud n° 03440-2015)
AR121312A2 (es) AGENTES DE ARNi, COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR ENFERMEDADES ASOCIADAS CON TRANSTIRETINA (TTR)
BR112018073328A2 (pt) combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade
CY1123678T1 (el) Χρηση αναστολεων μυοστατινης και θεραπειες συνδυασμου
CO2020015314A2 (es) Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso
CO7240361A2 (es) Composiciones de arni de serpinc1 y métodos de uso de las mismas
CL2018000899A1 (es) Compuestos y métodos para modular expresión de angiotensinógeno.
BR112018073329A2 (pt) combinação, composição farmacêutica, kit, método para tratar câncer, método para reduzir um nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade, método para reduzir metástase
UY36357A (es) Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa))
CR20190294A (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
UY35582A (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
CY1122975T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου alas1
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
AR102777A1 (es) COMPOSICIONES DE ARNi CONTRA TMPRSS6 Y MÉTODOS PARA SU USO
CL2021002262A1 (es) Composiciones y métodos para tratar laminopatías
ECSP19072372A (es) Moduladores de la expresión de pcsk9
BR112016002524A2 (pt) alvos moleculares para a prevenção e/ou tratamento de fibrose, cicatrizes hipertróficas e quelóides
BR112018005331A2 (pt) inibidores de pcna
BR112018006986A2 (pt) métodos e composições para contrações musculares indesejadas ou anormais
CL2021001246A1 (es) Moduladores de expresión irf5.
CL2022001481A1 (es) Composiciones de ácidos nucleicos
CO2021010304A2 (es) Composiciones de arni de serpinc1 y métodos de uso de las mismas